CA242高灵敏时间分辨荧光免疫分析及其初步应用

目的采用时间分辨荧光免疫分析技术（TRFIA）建立高灵敏的恶性肿瘤相关糖类抗原（CA）242的快速全自动检测方法并进行初步应用。方法以抗CA242单克隆抗体601#包被96孔微孔板,以Eu^3＋-N^2-[p-异氰酸苄基]-二乙烯三胺四乙酸标记抗CA242单克隆抗体242#,发光增强系统为以β-二酮体为主的增强液。采用平衡饱和法建立CA242 TRFIA,采用Auto DELFIA1235系统考核CA242 TRFIA,并进行健康人和胃癌患者血清样本的检测。结果该方法的批内和批间CV分别为2．92％和5．36％,平均回收率为98．75％,灵敏度为0．2kU／L,可测范围为0．2～200kU／L,最高浓度点计数的20％、50％、80％对应的效应点值（ED20、ED50、ED80）分别为25．2kU／L、53．3kU／L和112．5kU／L。CA50、CA19-9对CA242分别有15％和32％的交叉反应,癌胚抗原（CEA）、甲胎蛋白（AFP）、CA125对CA242 TRFIA均无交叉反应。Eu^3＋标记242#抗体于-20℃下保存6个月免疫反应性基本无损,同批试剂连续6个月应用分析结果稳定,检测健康体格检查人员的血清,样品的平均值为（6．52±5．15）kU／L,建议阳性阈值为17kU／L,临床结果与酶联免疫吸附测定（ELISA）的结果相符,r为0．916。116例胃癌患者血清CA242的阳性率为26．7％。结论CA242 TRFIA的灵敏度高、稳定性好,可用于血清CA242含量的免疫测定。     

组织多肽特异性抗原对胰腺癌患者的诊断价值

Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.     

组织多肽特异性抗原对胰腺癌患者的诊断价值

Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.     

组织多肽特异性抗原对胰腺癌患者的诊断价值

Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.     

组织多肽特异性抗原对胰腺癌患者的诊断价值

Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.     

组织多肽特异性抗原对胰腺癌患者的诊断价值

Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.     

组织多肽特异性抗原对胰腺癌患者的诊断价值

Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.     

组织多肽特异性抗原对胰腺癌患者的诊断价值

Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.     

组织多肽特异性抗原对胰腺癌患者的诊断价值

Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.     

组织多肽特异性抗原对胰腺癌患者的诊断价值

Objective To compare the diagnostic value of tissue polypeptide specific antigen (TPS) in serum, with the carbohydrate antigens (CA) 19-9, CA50, CA125 and CA242 in pancreatic carci-noma. Methods Serum TPS was measured with enzyme linked immunosorbent assay (ELISA). CA19-9 and CA125 were measured with chemiluminescent immunoassay. CAS0 and CA242 were measured with im-munoradiometric assay in 33 patients with pancreatitis, 34 patients with pathologically proven pancreatic car-cinoma, and 35 patients with non-pancreatic malignancies. Statistic analysis was carried out with SPSS 9.0 software. Results Patients with pancreatic carcinoma had relatively higher levels of TPS [(386.5± 315. 1) U/L] and CA19-9 [(10 820.9 ± 389.7) kU/L] when compared with patients with pancreatitis [(86. 2 ± 28.1) U/L and (61.5 ± 24.7) kU/L, respectively; F = 936. 42, P < 0. 001 ; F = 2217. 09, P < 0. 001], with a sensitivity and a specificity of 70.6% (48/68) and 57.4% (39/68), respectively, for TPS, and 82.4% (28/34) and 77.9% (53/68), respectively, for CA19-9. Diagnostic performance was further improved when TPS was assayed in combination with CA19-9, CA50, CA12.5 and CA242. Conclusion Serum TPS has an incremental value in complementing CA19-9 in the diagnosis of pancreatic carcinoma.     

B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价

目的 探讨B超引导下125I粒子组织间植入治疗晚期胰腺癌的临床价值。 方法 97例晚期胰腺癌患者在B超引导下术中植入125I粒子,采用疼痛数字分级法、实体瘤的疗效评价标准和肿瘤标志物糖类抗原242、19-9（CA242、CA19-9）的水平进行疗效评价,随访中观察患者的并发症及不良反应等。 结果 术前与术后1周、2周、1个月、3个月的患者疼痛评分比较,差异具有统计学意义（χ2=0.018、0.022、0.034、0.045,P均 < 0.05）;肿瘤完全缓解患者8例、部分缓解46例、稳定34例、疾病进展9例,总有效率为55.67%（54/97）;术前与术后1个月、3个月CA242、CA19-9的水平比较,差异具有统计学意义（χ2=0.027、0.029、0.017、0.022,P均 < 0.05）;治疗后中位生存时间为（8.0±4.5）个月,未出现严重并发症及不良反应。 结论 B超引导下125I粒子植入治疗晚期胰腺癌,疗效确切,安全性高,癌痛缓解明显。     

肿瘤标志物CEA、CA19-9、CA242联检在结直肠癌患者诊断中的应用

目的 探讨云南省大理州结直肠癌患者血清中肿瘤标志物癌胚抗原(CEA)、糖链蛋白抗原19-9(CA19-9)、糖链蛋白抗原242(CA242)单项或多项联检对结直肠癌的临床诊断价值.方法 应用电化学发光法和放免法检测89例结直肠癌患者和50例正常体检者的CEA、CA19-9和CA242水平.结果 三种肿瘤标志物在结直肠癌患者血清中含量均明显高于健康对照组(t分别为2.97、3.55和7.44,P均＜0.01);三种肿瘤标志物联检对结直肠癌的临床诊断效果明显优于各单项(CEA、CA19-9、CA242)和两项联检(CA242+CA19-9和CEA+CA19-9),差异有统计学意义(X2分别为30.552、32.076、18.365、7.130和8.862,P均＜0.01);三项联检可提高结直肠癌诊断的灵敏度(85.39%)和准确率(90.60%),但特异度下降(88.00%).结论 CEA、CA19-9和CA242可用于该地区结直肠痛的早期诊断和病情判断,三者联检可提高诊断效率.     

CA125和TPS在卵巢上皮性肿瘤诊疗中的意义

目的探讨血清CA125和TPS水平联合检测在卵巢肿瘤诊断中的价值,为卵巢肿瘤的诊断与病情监测提供新方法。方法用ELISA法分别检测卵巢良性肿瘤和卵巢癌患者术前及化疗前血清CA125和TPS水平。结果卵巢癌患者血清CA125和TPS水平均较良性肿瘤患者高,差异有显著性（P〈0.01）。血清CA125和TPS诊断卵巢癌的敏感度和特异度无差别。结论血清CA125和TPS水平可作为卵巢癌诊断与监测病情变化的临床指标。     

术前TPS及术后质量验证在125I粒子治疗眼眶肿瘤中的作用

目的 探讨术前TPS及术后质量验证在125I粒子近距离治疗眼眶肿瘤中的作用.方法 对2005年4月至2009年12月期间66例行125I粒子近距离治疗的眼眶肿瘤患者资料进行回顾性分析.66例中43例有数字影像资料者术前应用TPS,处方剂量140 Gy;余23例患者未行术前TPS,术中按间隔1 cm原则平行排列粒子.对所有66例患者术后均应用TPS进行质量验证.术后3、6、12和24个月分别对患者进行CT和(或)MRI随访.采用SPSS 17.0软件进行x2检验及Kaplan-Meier法log-rank 检验.结果 66例患者共植入125I粒子1070粒,平均(16.2±7.3)粒/人.TPS术前计划组及未计划组术后质量验证满意率分别为79.07％( 34/43)及43.48％( 10/23),差异有统计学意义(x2=8.542,P=0.003).10例患者术后失访,仅有术后验证资料,无影像学随访资料.TPS质量验证满意组术后3、6、12和24个月肿瘤局部复发率分别为0(0/37)、6.25％ (2/32)、13.64％ (3/22)和3/9,TPS质量验证不满意组局部复发率分别为5.26％ (1/19)、16.67％ (3/18)、30.77％ (4/13)和6/6,2组间差异有统计学意义(x2=9.017,P=0.0003).结论 TPS在125I粒子近距离治疗眼眶肿瘤中起重要作用.术前TPS是治疗成功的前提,TPS术后质量验证能较好地预测治疗效果,并指导临床确定进一步治疗方案.     

血清CA19-9水平对胰腺癌的诊断价值

探讨血清CA19 9水平对胰腺癌的诊断价值。回顾性分析 1993年 6月至 2 0 0 1年 6月间第二军医大学 3所附属医院胰腺癌住院患者共 10 31例 ,其中有明确CA19 9检测值者 778例。采用描述统计学方法和相关分析 ,研究CA19 9在胰腺癌诊断中的价值及与肿瘤分期和预后的关系。结果以CA19 9>37U/ml为参考值 ,发现 80 33%的胰腺癌患者血清CA19 9大于参考值 ,且发现CA19 9的水平与肿瘤的TNM分期有明显正相关 (r=0 5 13,P <0 0 1) ,与患者的生存期呈明显负相关 (r=- 0 4 2 7,P <0 0 1)。因此认为 ,CA19 9为诊断胰腺癌和判断病情分期及预后较好的参考指标     

Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy

The authors prospectively performed serum CA 19-9 assessment, ultrasound (US), computed tomography (CT), and CT-guided fine-needle aspiration biopsy (FNAB) of the pancreas in 81 consecutive patients with suspected chronic pancreatitis or pancreatic neoplasm. The final diagnosis was pancreatic cancer in 54 patients and chronic pancreatitis in 27 patients. CA 19-9 assessment, US, CT, and FNAB were considered nondiagnostic, respectively, in 0%, 25%, 19%, and 6% of cases. When a definite diagnosis was rendered, the positive predictive value was 90% for CA 19-9 assessment, 95% for US, 98% for CT, and 100% for FNAB; the negative predictive value was, respectively, 69%, 95%, 86%, and 100%. The accuracy of all diagnostic and nondiagnostic studies was 81% for CA 19-9 assessment, 72% for US, 77% for CT, and 94% for FNAB. It is concluded that CT-guided pancreatic FNAB is the most reliable examination for enabling differential diagnosis of pancreatic cancer and chronic pancreatitis. When the pancreas is well visualized at US, the negative predictive value for pancreatic cancer is more accurate than that of CA 19-9 assessment and CT.     

CT能谱成像在鉴别胰腺寡囊型浆液性囊腺瘤与黏液性囊性肿瘤中的价值

目的 探讨CT能谱成像定量分析在鉴别胰腺寡囊型浆液性囊腺瘤(SOA)与胰腺黏液性囊性肿瘤(MCNs)中的价值.方法 回顾性分析2010年2月至12月期间行能谱CT检查并经手术切除的胰腺囊性肿瘤27例,其中SOA为15例,MCNs为12例.采用x2检验比较两组间的非定量指标(性别、症状及病灶位置);采用t检验和Mann-Whitney检验比较定量指标(年龄、病灶大小、不同keV水平的CT值,有效原子序数,碘-水浓度,钙-水浓度),差异有统计学意义的指标通过判别分析法评估多参数联合诊断的价值.结果 与MCNs相比,SOA患者年龄较小、较少有症状、病灶较小.SOA的动脉期40～60keV及门静脉期40～50 keV CT值[分别为(36±13)、(26±8)和(19±6)HU,(43±14)和(30±10)HU],低于MCNs组上述期相和keV的CT值[分别为(62±23)、(40±15)和(27±10)HU,(61±25)和(40±16)HU](P＜0.05);SOA有效原子序数(动脉期和门静脉期分别为7.80±0.16和7.87±0.15)低于MCNs(动脉期和门静脉期分别为8.05±0.21和8.02±0.22)(P＜0.05);SOA动脉期的钙(水)浓度和碘(水)分别为(5±3)和(0.38±0.24)g/L,门静脉期分别为(7±3)和(0.48±0.24)g/L,均低于MCNs,动脉期分别为(11±4)和(0.78±0.32)g/L,门静脉期分别为(10±5)和(0.72±0.34)g/L(P＜0.05).判别分析结果显示,多参数联合[年龄、症状、病灶大小、40～50 keV的CT值、有效原子序数、动脉晚期碘(水)浓度及门静脉期钙(水)浓度]鉴别两者的准确率可达100%(27/27).结论 SOA与MCNs的囊性部分在CT能谱成像上具有不同特征.CT能谱成像多参数联合诊断可以准确区分SOA与MCNs.     

彩色多普勒超声血流阻力指数结合CA125对卵巢肿瘤的诊断价值

目的探讨彩色多普勒超声血流阻力指数(RI)结合肿瘤标志物CA125判断卵巢肿瘤良恶性的价值.资料与方法107例卵巢肿瘤患者采用Finkler 超声评分系统进行评分,经彩色多普勒超声检查测定 RI,同时测定患者血清 CA125判断卵巢肿瘤良恶性,并与术后病理进行对照.结果恶性卵巢肿瘤患者 Finkler 超声评分明显高于良性卵巢肿瘤患者,RI 值低于良性卵巢肿瘤患者,CA125明显高于良性卵巢肿瘤患者(P <0.01、P <0.05).Finkler超声评分、RI 结合 CA125对卵巢肿瘤良恶性诊断的敏感性及特异性分别为94.59%、89.47%,均高于单一检查方法.结论彩色多普勒超声、RI 及肿瘤标志物 CA125联合应用对提高卵巢肿瘤良恶性的诊断有一定临床价值.     

血磷、ALP、CA153及TPS对乳腺癌骨转移的诊断价值

 目的 探讨血磷及相关肿瘤标志物对乳腺癌骨转移的诊断价值。方法 对2012-01到2013-01山西省肿瘤医院674份住院治疗的乳腺癌病例进行检索,并调查其基本信息资料(年龄等)、临床资料(病理类型等),实验室资料(血磷、肿瘤标志物等)。随访至2018年底按照治疗后是否发生骨转移分为两组(转移组和对照组),统计分析两组患者各项指标之间的差异。结果 治疗前,乳腺癌骨转移组与对照组血磷含量无统计学差异(t=0.768,P=0.444),而治疗后,对照组的患者其血磷水平为(1.23±0.21)mmol/L,明显高于骨转移组的(1.04±0.21)mmol/L,差异有统计学意义(t=-7.51,P=0.000)。对治疗前后的血磷水平进行配对t检验,得到同样的结果,骨转移组治疗后的血磷水平明显降低(t=2.63,P<0.05),而对照组治疗后血磷水平明显升高(t=-5.66,P<0.0001)。治疗前后骨转移组ALP、CA153、TPS水平均显著高于对照组。结论 乳腺癌患者发生骨转移后血清磷水平明显降低;ALP、CA153、TPS可以作为早期监测乳腺癌骨转移的生物学标志。